GRAIL, Inc. (GRAL) shares tumbled 45.29 percent to $55.54, down $45.99 on Friday, after the company announced that its highly anticipated NHS-Galleri trial failed to meet its primary endpoint, despite showing some encouraging cancer detection trends. The stock is currently trading at $55.54, compared with a previous close of $101.53. It opened sharply lower at $48.88 and has traded between $48.00 and $56.75 during the session on the Nasdaq. Trading volume has surged to 8.05 million shares, well above its average volume of 0.89 million shares. The NHS-Galleri trial, conducted with England's National Health Service and enrolling more than 142,000 participants, did not demonstrate a statistically significant reduction in Stage III-IV cancers over three years. However, the company noted a favorable trend toward fewer late-stage cancers in a pre-specified group of 12 high-risk cancers after the initial screening round. The stock has traded in a 52-week range of $20.44 to $118.84.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.